# Risk: __Lack of effective pharmaceutical response__ (PBN__Risk_1602)

## Property: has_RiskSubject

* [general population](../Stakeholder/PBN__Stakeholder_9)
* [healthcare systems](../Stakeholder/PBN__Stakeholder_193)

## Property: has_RiskISO_Impact

* [Health and care](../RiskISO/PBN__RiskISO_Purpose_0)

## Property: has_RiskSource

* [kumar_role_2021](../Article/PBN__Article_140)

## Property: has_RiskName

Delayed response and increased mortality rates

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskTechnology

* [vaccine development technology](../Technology/PBN__Technology_917)
* [drug resistance surveillance technology](../Technology/PBN__Technology_918)

## Property: has_RiskOwner

* [none](../Stakeholder/PBN__Stakeholder_629)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskDescription

Ineffective vaccines and long development time for new vaccines and antibiotics

## Property: has_RiskISO_Purpose

* [Resilience](../RiskISO/PBN__RiskISO_Impact_2)

## Property: has_RiskMitigation

* [Improve surveillance for drug resistance, invest in vaccine development infrastructure](../RiskMitigation/PBN__RiskMitigation_2137)

